MIPS medicinal chemistry platform progresses partnered research programs via the Therapeutic Innovation Australia pipeline initiative

The funding has been awarded to the ATMCF and collaborators including biotechnology manufacturing company Cyclotek, the Murdoch Children’s Research Institute (MCRI), the University of South Australia (UniSA) Cancer Research Institute (CRI), Monash University Central Clinical School (CCS), University of Queensland, Pennsylvania State University and partners from the Monash University Department of Data Science and Artificial Intelligence (DSAI).

Glove

The ATMCF, established in 2012 at the Monash Institute of Pharmaceutical Sciences (MIPS), provides researchers with a medicinal chemistry facility to enable drug discovery development. The facility works with both academic and commercial collaborators to amalgamate key skills in translational medicinal chemistry and drug discovery.

The TIA-funded projects are targeting unmet therapeutic needs for a variety of critical illnesses including cancer, Multiple Sclerosis (MS), Acute Myeloid Leukaemia (AML), COVID-19 and the development of radioligands as diagnostic tools.

The partnership with Monash University CCS will develop small molecules to aid in neuroprotection and repair, creating new therapeutic agents which will lead to improved options for the treatment of MS. The partnership with the University of South Australia will develop novel small molecule inhibitors as therapeutics for all AML subtypes. The collaboration with the MCRI will develop cardioprotective drugs for use during chemotherapy treatments in children. Finally, the multi-institutional partnership with the DSAI, University of Queensland and Pennsylvania State University will develop an antiviral drug for the treatment of COVID-19.

Along with their partially TIA-funded project, Cyclotek have also engaged ATMCF on another project, with both projects developing radioligands to be used as diagnostic tools which could provide a more precise mechanism to detect disease status in patients. Director of MIPS, Professor Chris Porter, said the funding underlines the Faculty’s strength in both translational medicinal chemistry and in multi-sectoral partnerships.

“The ATMCF continues to demonstrate exceptional competencies in identifying critical unmet health needs and working with highly regarded partners to develop novel therapeutic outcomes for in-need populations,” says Professor Porter.

“On behalf of MIPS, I’d like to congratulate all our ATMCF staff and each of our collaborators for their success in receiving this funding. We look forward to watching these projects succeed and thrive.”

Therapeutic Innovation Australia manages funding from the NCRIS program funded by the Australian Department of Education, Skills and Employment. The Accelerator initiative, which is currently open for applications, enables researchers access to facilities around the country, including ATMCF.

For the full list of funded projects, please see below.

Australian Translational Medicinal Chemistry Facility funded projects:

  • Murdoch Children’s Research Institute (MCRI): $100,000 for the development of cardioprotective drugs for use during chemotherapy treatments.
  • University of South Australia (UniSA), Cancer Research Institute (CRI): $100,000 for the development of Acute Myeloid Leukaemia (AML) therapies.
  • Monash University, Central Clinical School (CCS): $100,000 for the development of drugs for the treatment of Progressive Multiple Sclerosis (MS).
  • Cyclotek: $355,000 to develop radioligands as diagnostic tools that will significantly shift the current treatment paradigm of certain types of cancer.
  • Monash University, Department of Data Science and Artificial Intelligence (DSAI), University of Queensland and Pennsylvania State University, USA: $100,000 for the development of an antiviral drug of the treatment of COVID-19.

Contact: Divya Krishnan

Phone: +61466910111

Email: divya.krishnan@monash.edu